Experimental study of the anticancer effect of gemcitabine combined with sirolimus on chemically induced urothelial lesions

Anticancer Research

Volumn 31, Issue 5, 2011, Pages 1637-1642

  Vasconcelos Nobrega C ^a   Colaco A ^b   Santos, L ^c,d   Vala, H ^a   Palomino, L F ^e   Lopes, C ^f   Oliveira, Paula A ^b  

^a POLYTECHNIC INSTITUTE OF VISEU   (Portugal)

^b UNIVERSITY OF TRÁS OS MONTES AND ALTO DOURO   (Portugal)

^c PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^d UNIVERSIDADE FERNANDO PESSOA   (Portugal)

^e UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^f UNIVERSITY OF PORTO   (Portugal)

Author keywords

BBN; Gemcitabine; Mice; Sirolimus; Urothelial lesion

Indexed keywords

GEMCITABINE; RAPAMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLADDER CANCER; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERANCE; HISTOPATHOLOGY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BUTYLHYDROXYBUTYLNITROSAMINE; DEOXYCYTIDINE; MALE; MICE; MICE, INBRED ICR; NEOPLASM INVASIVENESS; SIROLIMUS; SURVIVAL RATE; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 79958090014     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Franekova M, Halasova E, Bukovska E, Luptak J and Dobrota D: Gene polymorphisms in bladder cancer. Urol Oncol 26: 1-8, 2007.
2. Stein JP and Skinner DG: Radical cystectomy for invasive bladder cancer: long-term results of a standard procedure. World J Urol 3: 296-304, 2006. (Pubitemid 44143761)
3. Azria D, Jacot W, Culine S, Ychou M, Lemanski C and Dubois JB: Gemcitabine and ionizing radiations: radiosensitization or radiochemotherapy combination. Bull Cancer 89(4): 369-379, 2002. (Pubitemid 34664908)
4. Bergman AM, Pinedo HM and Peters GJ: Determinants of resistance to 2,2 difluorodeoxycytidine (gemcitabine). Drug Resist Updat 5: 19-33, 2002. (Pubitemid 34966646)
5. Belmunt J, Albiol S, Ramirez de Olano A, Pujadas J and Maroto P: Gemcitabine in the treatment of advanced transitional cell carcinoma of the urothelium. Ann Oncol 17(S5): v113-v117, 2006. (Pubitemid 43985219)
6. Andersson R, Aho U, Nilsson BI, Peters GJ, Pastor-Anglada M, Rasch W and Sandvold ML: Gemcitabine chemoresistance in pancreatic cancer: Molecular mechanisms and potential solutions. Scand J Gastroenterol 44: 782-786.
7. Raguse JD, Gath HJ, Bier J, Riess H and Oettle H: Gemcitabine in the treatment of advanced head and neck cancer. Clin Oncol 17: 425-429, 2005. (Pubitemid 41136137)
8. Mini E, Nobili S, Caciagli B, Landini I and Mazzei T: Cellular pharmacology of gemcitabine. Ann Oncol 17(S5): v7-vl2, 2006.
9. Gontero P and Tizzani A: Intravesical gemcitabine: State of the art. Eur Urol Supplements 6: 809-815, 2007.
10. Brocks CP, Buttner H and Bohle A: Inhibition of tumor implantation by intravesical gemcitabine in a murine model of superficial bladder cancer. J Urol 174: 1115-1118, 2005. (Pubitemid 41140697)
11. Beekman KW, Bradley D and Hussain M: New molecular targets and novel agents in the treatment of advanced urothelial cancer. Semin Oncol 34: 154-64, 2007. (Pubitemid 46436116)
12. Miyake M, Fujimoto K, Anai S, Ohnishi S, Nakai Y, Inoue T, Matsumura Y, Tomioka A, Ikeda T, Okajima E, Tanaka N and Hirao Y: Inhibition of heme oxygenase-1 enhances the cytotoxic effect of gemcitabine in urothelial cancer cells. Anticancer Res 30: 2145-2152, 2010.
13. Hidalgo M: New target, new drug, old paradigm. J Clin Oncol 22: 2270-2272, 2004.
14. Law BK: Rapamycin: An anticancer immunosuppressant? Crit Rev Oncol Hematol 56: 47-60, 2005.
15. Bjornsti MA and PJ Houghton: The TOR pathway: a target for cancer therapy, Nat Rev Cancer 4: 335-348, 2004.
16. Vignot S, FAivre S, Aguirre D and Raymond E: mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol 16: 525-537, 2005. (Pubitemid 40613318)
17. Wullschleger S, Loewith R and Hall MN: TOR signaling in growth and metabolism in growth and metabolism. Cell 124: 471-484, 2006.
18. Oliveira PA, Arantes-Rodrigues R, Sousa-Diniz C, Colaço A, Lourenço L, De La Cruz LF, Da Silva VM, Afonso J, Lopes C and Santos L: The effects of sirolimus on urothelial lesions chemically induced in ICR mice by BBN. Anticancer Res 29: 3221-3226, 2009.
19. Seager CM, Puzio-Kuter AM, Patel T, Jain S, Cordon-Cardo C, Mc Kiernan J and Abate-Shen C: Intravesical delivery of rapamycin suppresses tumorigenesis in a mouse model of progressive bladder cancer. Cancer Prev Res 2: 1008-1014, 2009.
20. Parada B, Reis F, Figueiredo A, Nunes P, Teixeira-Lemos E, Garrido P, Sereno J, Pinto R, Cunha MF, Neto P, Santos P, Velada I, Mota A and Teixeira F: Inhibition of bladder tumour growth by sirolimus in an experimental carcinogenesis model. BJU Int 107: 135-143, 2011.
21. Pinto-Leite R, Botelho P, Ribeiro E, Oliveira PA and Santos L: Effect of sirolimus on urinary bladder cancer T24 cell line. J Exp Clin Cancer Res Doi:10.1186/1756-9966-28-3, 2009.
22. Hansel D, Platt E, Orloff M, Harwalker J, Sethu S, Hicks JL, De Marzo A, Steinle RE, Hsi ED, Theodorescu D, Ching CB and Eng C: Mammalian target of rapamycin (mTOR) regulates cellular proliferation and tumor growth in urothelial carcinoma. Am J Pathol 176: 3062-3072, 2010.
23. Okada T, Sawada T and Kubota K: Rapamycin enhances the antitumor effect of gemcitabine in pancreatic cancer cells. Hepatogastroenterology 54: 2129-2133, 2007.
24. Mueller MT, Hermann PC, Witthauer J, Rubio-Viqueira B, Leicht SF, Huber S, Ellwart JW, Mustafa M, Bartenstein P, D'Haese JG, Schoenberg MH, Berger F, Jauch KW, Hidalgo M and Heeschen C: Combined targeted treatment to eliminate tumorigenic cancer stem cells in human pancreatic cancer. Gastroenterology 137: 1102-1113, 2009.
25. Mondesire WH, Jian W, Zhang H, Ensor J, Hung MC, Mills GB and Meric-Burnstam F: Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells. Clin Cancer Res 10: 7031-7042, 2004.
26. Epstein JI, Amin MB, Reuter VR and Mostofi FK: The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol 22: 1435-1448, 1998. (Pubitemid 28550639)
27. Nativ O, Dalai E, Laufer M, Sabo E and Aronson M: Antineoplastic effect of gemcitabine in an animal model of superficial bladder cancer. Urology 64: 845-848, 2004. (Pubitemid 39446086)
28. Horinaga M, Fukuyama R, Iida M, Yanaihara H, Nakahira Y, Nonaka S, Deguchi N and Asakura H: Enhanced antitumor effect of coincident intravesical gemcitabine plus BCG therapy in an orthotopic bladder cancer model. Urology 76: 1267.e1-1267.e6, 2010.
29. Merimsky O, Gorzalczany Y and Sagi-Eisenberg R: Molecular impacts of rapamycin-based drug combinations: Combining rapamycin with gemcitabine or imatinib mesylate (Gleevec) in a human leiomyosarcoma model. Int J Oncol 31: 225-232, 2007.
30. Giovanneti E, Danesi R, Mey V, Nannizzi S, Pasqualetti G and Del Tacca M: In vitro studies on gemcitabine combinations with other antiblastics. Ann Oncol 17(S5): v17-v19, 2006.